SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (a) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)
TriVascular Technologies, Inc.
(Name of Issuer)
Common Stock, par value $0.01
per share
(Title of Class of Securities)
89685A102
(CUSIP Number)
Matthew Potter
c/o Delphi Ventures
160 Bovet Rd, Suite 408
San Mateo, CA 94402
(650) 854-9650
COPY TO:
Christine Wichrowski, Esq.
c/o Gunderson Dettmer Stough Villeneuve
Franklin & Hachigian, LLP
1200 Seaport Boulevard, Redwood City, California
94063
(650) 321-2400
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 3, 2016
(Date of Event Which Requires Filing
of this Statement)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.
Note: Schedules filed
in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.
* The remainder of
this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class
of securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
(Continued on following
pages)
CUSIP NO. 89685A102 |
13D |
Page 2 of 16 |
1 |
NAME OF REPORTING
SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Delphi Ventures VIII,
L.P. (“Delphi VIII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
PN |
CUSIP NO. 89685A102 |
13D |
Page 3 of 16 |
1 |
NAME OF REPORTING
SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Delphi BioInvestments
VIII, L.P. (“DBI VIII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
PN |
CUSIP NO. 89685A102 |
13D |
Page 4 of 16 |
1 |
NAME OF REPORTING
SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Delphi Management Partners
VIII, L.L.C. (“DMP VIII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
OO |
CUSIP NO. 89685A102 |
13D |
Page 5 of 16 |
1 |
NAME OF REPORTING PERSON
Delphi Ventures VII, L.P.
(“Delphi VII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON |
PN |
CUSIP NO. 89685A102 |
13D |
Page 6 of 16 |
1 |
NAME OF REPORTING
SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Delphi BioInvestments
VII, L.P. (“DBI VII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON |
PN |
CUSIP
NO. 89685A102 |
13D |
Page 7 of 16 |
1 |
NAME OF REPORTING
SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Delphi Management Partners
VII, L.L.C. (“DMP VII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON |
OO |
CUSIP NO. 89685A102 |
13D |
Page 8 of 16 |
1 |
NAME OF REPORTING PERSON James J. Bochnowski (“Bochnowski”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
0 shares. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
0 shares. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
IN |
CUSIP NO. 89685A102 |
13D |
Page 9 of 16 |
1 |
NAME OF REPORTING PERSON David L. Douglass (“Douglass”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
0 shares. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
0 shares. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
IN |
CUSIP NO. 89685A102 |
13D |
Page 10 of 16 |
1 |
NAME OF REPORTING PERSON Deepika R. Pakianathan (“Pakianathan”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
0 shares. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
0 shares. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
IN |
CUSIP NO. 89685A102 |
13D |
Page 11 of 16 |
1 |
NAME OF REPORTING PERSON Douglas A. Roeder (“Roeder”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
0 shares. |
6 |
SHARED VOTING POWER
0 shares. |
7 |
SOLE DISPOSITIVE POWER
0 shares. |
8 |
SHARED DISPOSITIVE POWER
0 shares. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
0 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
0.0% |
12 |
TYPE OF REPORTING PERSON* |
IN |
CUSIP NO. 89685A102 |
13D |
Page 12 of 16 |
ITEM 1. SECURITY AND ISSUER.
This Amendment No. 1 to Schedule 13D relates
to the beneficial ownership of common stock, par value $0.01 per share (the “Common
Stock”), of TriVascular Technologies, Inc., a Delaware corporation (the “Company”), by the Reporting Persons
and supplements and amends the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”)
on April 24, 2014 (the “Schedule 13D”). Only those items that are hereby reported are amended; all other items remain
unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Schedule 13D. The Company’s
principal executive offices are located at 3910 Brickway Blvd., Santa Rosa, CA 95403.
ITEM 2. IDENTITY AND BACKGROUND.
Item 2 (a-c, f) of the Schedule 13D
are hereby amended and restated in their entirety as follows:
(a-c, f) This Schedule
13D is being filed on behalf of: (i) Delphi Ventures VIII, L.P., a Delaware limited partnership (“Delphi VIII”), (ii)
Delphi BioInvestments VIII, L.P., a Delaware limited partnership (“DBI VIII”), (iii) Delphi Management Partners
VIII, L.L.C., a Delaware limited liability company (“DMP VIII”), (iv) Delphi Ventures VII, L.P., a Delaware limited
partnership (“Delphi VII”), (v) Delphi BioInvestments VII, L.P., a Delaware limited partnership (“DBI VII”),
(vi) Delphi Management Partners VII, L.L.C., a Delaware limited liability company (“DMP VII”), (vii) James J. Bochnowski
(“Bochnowski”), a citizen of the United States, (viii) David L. Douglass (“Douglass”), a citizen of the
United States, (ix) Deepika R. Pakianathan (“Pakianathan”), a citizen of the United States, and (x) Douglas A. Roeder
(“Roeder”), a citizen of the United States (the foregoing entities and individuals are collectively referred to as
the “Reporting Persons”).
Delphi VIII, DBI VIII, Delphi VII and DBI
VII (collectively, the “Delphi Funds”) are venture capital funds. DMP VIII is the general partner of each of Delphi
VIII and DBI VIII. DMP VII is the general partner of each of Delphi VII and DBI VII. Bochnowski, Douglass, Pakianathan and Roeder
are the managing members of DMP VIII and DMP VII (collectively, and with respect to each of DMP VIII and DMP VII, the “Managing
Members”). The principal business office of the Reporting Persons is 160 Bovet Road, Suite 408, San Mateo, CA 94402.
ITEM 3. SOURCE AND AMOUNT OF FUNDS
OR OTHER CONSIDERATION.
Item 3 of the Schedule 13D is hereby amended
to add the following statements:
TriVascular Technologies,
Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger, dated as of October 26,
2015 (the “Merger Agreement”), by and among the Company, Endologix, Inc., a Delaware corporation (“Endologix”
or “Parent”), and Parent’s wholly-owned subsidiary, Teton Merger Sub Inc., a Delaware corporation (“Merger
Sub”). Pursuant to the Merger Agreement, at the effective time of the Merger, Merger Sub was merged with and into the Company
(the “Merger”) with the Company surviving the Merger as a direct wholly-owned subsidiary of the Parent. The Closing
of the Merger occurred on February 3, 2016.
At the effective time
and as a result of the Merger, each share of the Company’s Common Stock outstanding immediately prior to the effective time
of the Merger (other than any shares of the Company’s Common Stock held by Company stockholders demanding appraisal of such
shares and who have complied with all applicable appraisal procedures and requirements in accordance with Delaware law and other
than cancelled shares described below) was automatically converted into the right to receive merger consideration equal to 0.631
share of Endologix’s common stock and $0.34 in cash, for an aggregate value, based on the closing price of Endologix’s
common stock on February 2, 2016, of $4.95 per share. Each share of the Company’s Common Stock outstanding immediately
prior to the effective time of the Merger that was owned or held in treasury by the Company, owned by Endologix, any subsidiary
of Endologix (including Merger Sub), the Company or any subsidiary of the Company, was automatically cancelled and ceased to exist,
and no consideration was delivered in exchange therefor.
In connection with
the Merger, Endologix paid approximately $106,828,804 in aggregate consideration to the stockholders of the Company, consisting
of (i) approximately $7,410,301 in cash and (ii) 13,618,973 shares of Endologix common stock.
CUSIP NO. 89685A102 |
13D |
Page 13 of 16 |
In connection with
the Merger, the Delphi Funds received approximately $1,202,209 in cash and 2,231,158 shares in the aggregate of Endologix’s
common stock, in exchange for all of its securities of the Company.
On February 3,
2016, following the effective time of the Merger, the Company requested that the NASDAQ Stock Market file with the SEC an application
on Form 25 to withdraw the Company’s Common Stock from listing on the NASDAQ Global Select Market and terminate the registration
of the Company’s common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). In addition, the Company intends to file with the SEC a certification and notice of termination on Form 15 to terminate
the registration of its common stock under the Exchange Act and to suspend its reporting obligations under Section 15(d) of
the Exchange Act.
No part of the purchase
price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.
The foregoing description
of the terms of the Merger Agreement in Item 3 is intended as a summary only and is qualified in its entirety by reference to the
Merger Agreement which is filed as an exhibit to this Schedule 13D and incorporated by reference herein.
ITEM 4. PURPOSE
OF TRANSACTION.
Item 4 of the Schedule 13D is hereby amended
to add the following statements:
TriVascular Technologies,
Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger, dated as of October 26,
2015 (the “Merger Agreement”), by and among the Company, Endologix, Inc., a Delaware corporation (“Endologix”
or “Parent”), and Parent’s wholly-owned subsidiary, Teton Merger Sub Inc., a Delaware corporation (“Merger
Sub”). Pursuant to the Merger Agreement, at the effective time of the Merger, Merger Sub was merged with and into the Company
(the “Merger”) with the Company surviving the Merger as a direct wholly-owned subsidiary of the Parent. The Closing
of the Merger occurred on February 3, 2016.
At the effective time
and as a result of the Merger, each share of the Company’s Common Stock outstanding immediately prior to the effective time
of the Merger (other than any shares of the Company’s Common Stock held by Company stockholders demanding appraisal of such
shares and who have complied with all applicable appraisal procedures and requirements in accordance with Delaware law and other
than cancelled shares described below) was automatically converted into the right to receive merger consideration equal to 0.631
share of Endologix’s common stock and $0.34 in cash, for an aggregate value, based on the closing price of Endologix’s
common stock on February 2, 2016, of $4.95 per share. Each share of the Company’s Common Stock outstanding immediately
prior to the effective time of the Merger that was owned or held in treasury by the Company, owned by Endologix, any subsidiary
of Endologix (including Merger Sub), the Company or any subsidiary of the Company, was automatically cancelled and ceased to exist,
and no consideration was delivered in exchange therefor.
In connection with
the Merger, Endologix paid approximately $106,828,804 in aggregate consideration to the stockholders of the Company, consisting
of (i) approximately $7,410,301 in cash and (ii) 13,618,973 shares of Endologix common stock.
In connection with
the Merger, the Delphi Funds received approximately $1,202,209 in cash and 2,231,158 shares in the aggregate of Endologix’s
common stock, in exchange for all of its securities of the Company.
On February 3,
2016, following the effective time of the Merger, the Company requested that the NASDAQ Stock Market file with the SEC an application
on Form 25 to withdraw the Company’s Common Stock from listing on the NASDAQ Global Select Market and terminate the registration
of the Company’s common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). In addition, the Company intends to file with the SEC a certification and notice of termination on Form 15 to terminate
the registration of its common stock under the Exchange Act and to suspend its reporting obligations under Section 15(d) of
the Exchange Act.
CUSIP NO. 89685A102 |
13D |
Page 14 of 16 |
In accordance with
the terms of the Merger Agreement, Douglas A. Roeder resigned from his position as a member of the Company’s Board of Directors,
and any committees thereof, effective as of the closing of the Merger.
ITEM 5. INTEREST IN SECURITIES OF
THE ISSUER.
Items 5(a), 5(b), 5(c) and 5(e) of the
Original Schedule 13D are hereby amended and restated in their entirety as follows:
(a,b) Regarding
aggregate beneficial ownership, see Row 9 of the cover page of each Reporting Person. Regarding percentage beneficial ownership,
see Row 11 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 5 of the cover page of each
Reporting Person. Regarding shared power to vote shares, see Row 6 of the cover page of each Reporting Person. Regarding sole power
to dispose of shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row
8 of the cover page of each Reporting Person.
(c) Except as
set forth in Item 3 above, the Reporting Persons have not effected any transaction in the Common Stock of the Company during
the past 60 days.
(e) The
Reporting Persons ceased to be beneficial owners of 5% or more of the Company’s Common Stock on February 3, 2016.
ITEM 7. MATERIAL
TO BE FILED AS EXHIBITS.
Item 7 of the Schedule 13D is hereby amended
to add the following:
EXHIBIT C |
Agreement and Plan of Merger |
CUSIP NO. 89685A102 |
13D |
Page 15 of 16 |
SIGNATURES
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 10, 2016
DELPHI MANAGEMENT PARTNERS VIII, L.L.C. |
|
JAMES J. BOCHNOWSKI |
|
|
|
DELPHI VENTURES VIII, L.P. |
|
DAVID L. DOUGLASS |
By: |
Delphi Management Partners VIII, L.L.C. |
|
|
|
General Partner |
|
DEEPIKA R. PAKIANATHAN |
|
|
|
|
DELPHI BIOINVESTMENTS VIII, L.P. |
|
DOUGLAS A. ROEDER |
By: |
Delphi Management Partners VIII, L.L.C. |
|
|
|
General Partner |
|
|
|
|
|
|
DELPHI MANAGEMENT PARTNERS VII, L.L.C. |
|
|
|
|
|
DELPHI VENTURES VII, L.P. |
|
|
By: |
Delphi Management Partners VII, L.L.C. |
|
|
|
General Partner |
|
|
|
|
|
|
DELPHI BIOINVESTMENTS VII, L.P. |
|
|
By: |
Delphi Management Partners VII, L.L.C. |
|
|
|
General Partner |
|
|
By: |
/s/ Matthew T. Potter |
|
By: |
s/ Matthew T. Potter |
|
Matthew T. Potter, Chief Financial Officer/Attorney-In-Fact for the above-listed entities* |
|
|
Matthew T. Potter, Chief Financial Officer/Attorney-In-Fact for the above-listed individuals* |
* Signed pursuant to a Power of Attorney
already on file with the appropriate agencies.
CUSIP NO. 89685A102 |
13D |
Page 16 of 16 |
exhibit C
Agreement and Plan of Merger, dated as
of October 26, 2015, by and among Endologix, Inc., Teton Merger Sub, Inc. and the Company (incorporated by reference to Annex A
of the Company’s Proxy Statement filed with the SEC on January 8, 2016).
TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Historical Stock Chart
From Jun 2024 to Jul 2024
TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Historical Stock Chart
From Jul 2023 to Jul 2024